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Abstract
The usefulness of sensory symptoms in the assessment of diabetic polyneuropathy is unclear. In the present study,
we studied the hypothesis that pain is associated with small nerve fibre function, and that sensory alteration is
associated with large nerve fibre function. In addition, we assessed the reproducibility and the ability to detect
changes in clinical status over time of the nerve function tests currently used in clinical trials. Patients (78) with stable
diabetic polyneuropathy were examined on three separate occasions with a test–retest interval of 17 and 52 weeks.
Small nerve fibre function was measured using temperature discrimination thresholds for warmth (TDTwarmth) and
cold (TDTcold). Large nerve fibre function was measured by testing sensory and motor nerve conduction velocities
(SNCV and MNCV) and vibration perception thresholds (VPT). Neuropathic pain was only significantly associated
with TDTcold, and with the MNCV of the tibial nerve. Sensory alteration was associated with almost all nerve
function tests except the SNCV and MNCV of the ulnar nerve. The measurements of symptom severity and the nerve
function tests all proved to be sufficiently reproducible. The standardized smallest detectable difference on group level
(SDD) of the measurement of sensory alteration and neuropathic pain were almost the same (9% and 12%,
respectively). Among the nerve function tests, the SNCV and MNCV had the smallest SDD (3–4%), and were,
therefore, potentially the most responsive instruments. The SDD of the TDT was greater than the VPT (9–14% vs
21–28%, respectively). In conclusion, neuropathic pain was not associated with small nerve fibre function, and
sensory alteration was associated with both large and small fibre function. In addition, the standardized measurement
of symptom severity, the SNCV and MNCV tests, and the VPT test appear to be useful for monitoring the course
of polyneuropathy in clinical trials. © 2000 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Polyneuropathy is a very common complication
of diabetes mellitus that is frequently accompa-
nied by distressful sensory symptoms [1]. Polyneu-
ropathy is considered to be a major causal factor
in the majority of foot ulcerations in diabetic
patients [2,3]. The incidence of foot ulceration can
be reduced if polyneuropathy is diagnosed at an
early stage [4–6].
In daily clinical practice, sensory symptoms are
often the reason for a diabetic patient to consult
his physician [7]. However, the usefulness of mea-
suring sensory symptoms in the assessment of
polyneuropathy in daily clinical practice is un-
clear, because lack of clarity exists about the
relationship between nerve function and symptom
severity of polyneuropathy.
Recently, by means of a questionnaire, we have
established the existence of two dimensions of
sensory symptoms in patients with diabetic
polyneuropathy [8,9]. In addition to a dimension
of neuropathic pain, there appeared to be a di-
mension of sensory alteration complaints, which
included paraesthesiae. It was also demonstrated
that the latter was predominantly associated with
nerve dysfunction, irrespective the type of nerve
fibre damage [8]. The existence of this relationship
is potentially of great clinical importance, because
it indicates that enquiring about sensory alter-
ation complaints may be useful in the assessment
of diabetic polyneuropathy in daily clinical prac-
tice. However, the origin of the existence of the
two separate dimensions of sensory symptoms is
still unclear. Previous reports have shown that
neuropathic pain may be caused by small nerve
fibre damage [10–13]. Furthermore, it has been
shown that painless neuropathy and foot ulcera-
tion was associated with large nerve fibre abnor-
mality [14]. Therefore, we hypothesized that the
severity of neuropathic pain is associated with
small nerve fibre damage, and that the severity of
complaints of sensory alteration is associated with
large nerve fibre damage.
Several methods are currently used for the as-
sessment of small and large nerve fibre function.
In consensus meetings, both the testing of nerve
conduction velocities and the testing of vibration
perception thresholds (VPT) are recommended as
valid and reproducible tests for assessing large
nerve fibre function, and the testing of warm and
cold thermal discrimination thresholds
(TDTwarmth and TDTcold, respectively) is recom-
mended for the assessment of small nerve fibre
function [15–18]. For this reason, these tests were
used for the assessment of nerve function in the
present study.
The outcome of the nerve conduction velocity
tests, VPT and TDT, can be influenced by many
external factors. In order to ensure the reproduci-
bility of the tests, they must be performed in a
standardized manner. However, reproducibility of
the tests might differ among centres [18]. More-
over, when the course of polyneuropathy is moni-
tored, as happens in clinical trials, the methods
chosen to assess nerve function and symptom
severity must not only be reproducible, but should
also be able to detect changes over time in pa-
tients. However, there is very little published data
on the ability of tests of nerve conduction veloc-
ities, VPT and TDT to detect changes of nerve
function [19].
The first aim of this study was to assess the
(construct) validity of the measurement of the
severity of neuropathic pain and sensory alter-
ation complaints. Therefore, we investigated
whether the severity of neuropathic pain was pre-
dominantly associated with small nerve fibre func-
tion, and the severity of sensory alteration
complaints was predominantly associated with
large nerve fibre function. In addition, we studied
the reproducibility (test–retest reliability) and the
ability to detect changes over time both of the
measurement of sensory symptom severity and of
the tests of nerve conduction velocities, VPT and
TDT.
2. Materials and methods
2.1. Patients
A total of 78 patients participated in the study.
Inclusion criteria for entering the study were:
insulin-dependent (Type 1) or non-insulin depen-
dent (Type 2) diabetes mellitus, treated with in-
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sulin for a period of at least 6 months; age 20–65
years; familiarity with home glucose monitoring
and self-regulation; stable metabolic control of
diabetes; established polyneuropathy defined as at
least one abnormal nerve conduction velocity un-
der the 5th-percentile (P5-value) of normal aged-
matched controls [20], together with an abnormal
value of the VPT or TDTwarmth measured at the
foot above the P95-value of normal aged-matched
controls [21–23].
Excluded from participation in the study were
patients with other putative causes of polyneu-
ropathy, using neurotoxic drugs, neuropathic foot
ulcerations or arterial insufficiency in the legs.
The study duration was 52 weeks. Patients were
asked to visit the research ward at the start of the
study, and again after 17 and 52 weeks. For each
patient the assessments were made by the same
investigator throughout the study and at the same
time of day, using the same instruments.
3. Nerve function tests
3.1. Small ner6e fibre function
Thermal thresholds were assessed at the ventral
side of the left wrist with a temperature threshold
tester (Medelec Triple T, Old Woking, UK). The
two alternative forced-choice method was used to
measure the temperature discrimination threshold
for warmth (TDTwarmth) and cold (TDTcold). The
TDT was expressed as the change from the basic
skin temperature in °C detected by the patient.
Details of this testing procedure have been de-
scribed elsewhere [21,22].
3.2. Large ner6e fibre function
Vibration perception threshold (VPT) expressed
in mm was assessed at the dorsum of the second
metacarpal bone of the left hand and the dorsum
of the first metatarsal bone of the left foot. The
VPT was measured using a Vibrameter (Somedic,
Stockholm, Type 4). The amplitude of a probe,
vibrating at 100 Hz, was increased from zero and
the subject was asked to indicate the moment
when he or she started to feel the vibration
(method of limits). Details of this testing proce-
dure have been described elsewhere [23,24].
Sensory nerve conduction velocity (SNCV) of
the right ulnar nerve and left sural nerve was
measured antidromically using surface electrodes.
Because at the baseline measurements sural nerve
action potentials could only be evoked in 32
patients (41%), this nerve function measurement
was not included in the analysis. Motor nerve
conduction velocity (MNCV) of the left tibial
nerve and right ulnar nerve was recorded using
surface electrodes over the abductor hallucis and
digiti minimi muscles, respectively. Motor and
sensory nerve conduction velocities were mea-
sured and expressed in m/s. The limbs were
heated in a warm bath for 30 min before the
examination was carried out, and during the ex-
amination skin temperature was maintained at
34°C.
3.3. Assessment of symptom se6erity
The Diabetes symptom checklist-Type 2 (DSC-
Type 2) was used to measure the severity of
sensory symptoms [9]. This instrument consists of
34 questions about diabetes-related symptoms. It
has a 10-item sensory polyneuropathy dimension,
sub-divided into two different sub-dimensions, in-
cluding six questions on sensory alteration: (1)
tingling sensations in the hands/fingers; (2) numb-
ness of the hands; (3) strange sensation in the legs
or feet; (4) tingling sensation in the lower legs; (5)
numbness of the feet; (6) tingling sensation in the
arms/legs at night, and four questions on neu-
ropathic pain: (7) shooting pains in the legs; (8)
burning pains in the legs; (9) pain in the legs
during walking; (10) burning pain in the calves at
night. By means of this checklist the frequency of
occurrence of the symptoms was measured. The
possible answers were scored as: 0=not at all,
1=one or more times a month, 2=one or more
times a week and, 3=daily. The sum of the scores
of the frequency of occurrence of the symptoms
was computed as a measure of severity. This
outcome varied between 0 (no symptoms) and 18
(severe symptoms) for the sub-dimension of sen-
sory alteration, and between 0 and 12 for the
sub-dimension of neuropathic pain.
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3.4. Laboratory examinations
In the course of the study an attempt was made
to maintain stable glycaemic control. Glycosy-
lated haemoglobin (HbA1c) was used as a parame-
ter of glycaemic control. In order to exclude the
possible influence of changes in glycaemic control
on symptoms and nerve function, HbA1c was
measured every eight weeks (92 weeks), during
the course of the study.
3.5. Statistical analysis
A logarithmic transformation (log10) was car-
ried out in order to normalize the distribution of
the outcome of the VPT and TDT assessments.
To investigate the stability of nerve function dur-
ing the course of the study, the mean of the
test–retest differences and the standard deviation
of these differences in the MNCV of the tibial
nerve and TDTwarmth were computed.
Construct validity was determined by assessing
the correlation between the tests of small and
large nerve fibre function, on the one hand, and
neuropathic pain and sensory alteration on the
other hand, and was assessed by using Pearson
correlation coefficients.
The test–retest reproducibility was expressed in
two ways. First of all, Pearson correlation coeffi-
cients were calculated between the baseline and
follow-up measurements. Subsequently, the
smallest detectable statistical significant mean dif-
ference in test outcome over time, within a group
of 100 patients, was assessed based on the esti-
mated variance in test–retest differences. This was
calculated by using a sample-size formula, as pro-
posed by Guyatt, and was expressed as the
smallest detectable statistically significant test–
retest difference (SDD) on group level, with the
assumption that a=0.05, b=0.10 and group
size=100.[25] Using the sample size formula, the
SDD of the tests in groups of other sizes (i.e. 50)
can easily be computed.
Sample size formula: SDD=
'(Za+Zb)2×s2
Nt
SDD is the smallest detectable statistically signifi-
cant mean test–retest difference measurements
over time in groups; s2 is the variance of intra-
person difference over time between subjects, esti-
mated by SD2dif, the calculated standard deviation
of intra-subject differences between test and
retest; a=0.05 (Za=1.96); b=0.10 (Zb=
1.282); and Nt=100 (group size).
In order to permit comparison between the
SDD of the different tests of nerve function, the
SDD was also expressed as the percentage of
change for the corresponding mean of the pooled
data of test and retest.
4. Results
Table 1 lists the characteristics of the patients
participating in the study. The number of patients
for whom data were available in Tables 2 and 3
was less than 78, for several reasons: three pa-
tients discontinued before the end of the study
because they no longer wished to co-operate; thir-
teen questionnaires were missing at baseline and
12 questionnaires at 17 weeks, because they were
not returned; for two of the returned question-
naires the total score could not be calculated,
because one or more of the questions had not
been answered.
According to repeated HbA1c measurements,
metabolic control was stable during the course of
the study. The mean HbA1c (%) at 17 weeks was
8.3 (range 4.9–12.8), and the mean HbA1c (%) at
52 weeks was 8.2 (range 5.5–12.8).
The nerve function of the patients was stable
during the course of the study. The mean of the




49.5 (range 27–65)Mean age (years)a
Gender (m/f ratio) 43/35
Mean diabetes duration (years)a 21.3 (range 1–46)
8.3 (range 5.1–13.0)Mean HbA1c (%)
a
a Measured at baseline.
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Table 2
Pearson correlations between symptom severity and nerve fibre function at baselinea
N Symptom severity
Sensory alteration Pain
r P-value r P-value
Large ner6e fibre function
−0.43MNCVtibial 0.00157 −0.29 0.03
−0.23 0.0663 −0.21MNCVulnar 0.07
SNCVulnar 61 −0.16 0.23 −0.10 0.23
0.30 0.0263 −0.16VPTfoot 0.20
0.26 0.04 −0.14 0.30VPThand 62
Small ner6e fibre function
0.53TDTwarm 0.000162 0.16 0.22
TDTcold 62 0.33 0.009 0.26 0.04
a n, number of patients for whom data were available. MNCV: motor nerve conduction velocity, expressed in m/s; SNCV: sensory
nerve conduction velocity, expressed in m/s; VPT: vibration perception threshold, expressed in mm, 10log-transformed; TDT:
temperature discrimination threshold assessed at the left wrist and expressed in oC, 10log-transformed.
Table 3
Test–retest reproducibility and smallest detectable difference (SDD) on group level of symptom severity and nerve function tests,
performed at baseline and follow-up at 17 weeks
na Mean (IQR)b Reproducibility SDD (%)e
Test–retest correlationc SDdif
d
8.81 (4.0–12.0) 0.89Sensory alteration 2.5859 0.84 (9)
4.83 (2.0–6.5) 0.85 1.7660 0.57Pain (12)
MNCVtibial 67 38.74 (35.5–42.0) 0.70 4.43 1.44 (4)
55.46 (52.5–59.1) 0.56 5.8474 1.89MNCVulnar (3)
71SNCVulnar 44.71 (42.5–48.0) 0.67 4.11 1.33 (3)
1.07 (0.69–1.34) 0.77VPTfoot 0.3175 0.1 (9)
0.28 (0.18–0.32) 0.92 0.1174 0.04VPThand (14)
0.33 (0.14–0.44) 0.76 0.21TDTwarm 0.0773 (21)
0.25 (0.10–0.33) 0.49 0.2273 0.07TDTcold (28)
a Number of patients for whom the data were available.
b Mean and inter-quartile range of the pooled data of test and retest.
c Pearson correlation coefficient.
d Standard deviation of the within-subject differences between the two measurements, SDD, smallest detectable test–retest
difference over time within groups (n=100).
e SDD standardized to corresponding mean of the pooled data of test and retest. MNCV: motor nerve conduction velocity,
expressed in m/s; SNCV: sensory nerve conduction velocity, expressed in m/s; VPT: vibration perception threshold, expressed in mm,
10log-transformed; TDT: temperature discrimination threshold, expressed in °C, 10log-transformed.
tibial nerve and the TDTwarmth was very small and
did not significantly differ from zero (data not
shown). Moreover, the standard deviation of the
test–retest differences was relatively small (Table
3).
4.1. Construct 6alidity of the measurements of
symptom se6erity
The associations between the measurements of
symptom severity on the one hand, and nerve
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function on the other hand, assessed at baseline,
are presented in Table 2. The sub-dimension of
sensory alteration was correlated with almost all
nerve function tests, except the SNCV and
MNCV of the ulnar nerve. The sub-dimension of
neuropathic pain was only correlated with the
MNCVtibial and the TDTcold. Therefore, sensory
alteration unexpectedly not only performed better
with regard to large nerve fibre function, but also
with regard to small nerve fibre function.
4.2. Reproducibility
The reproducibility of the assessment of sensory
symptom severity and nerve function tests, for the
test–retest interval of 17 weeks, is presented in
Table 3. The test–retest correlation coefficients of
the assessments of the severity of sensory alter-
ation complaints and neuropathic pain were 0.89
and 0.85, respectively. Test–retest correlation co-
efficients of nerve function tests were between 0.49
and 0.92. The figures for the test–retest interval of
52 weeks were almost the same (data not shown).
The reproducibility of the symptom severity-scale
was scarcely influenced by the length of the test–
retest interval. The test–retest correlation coeffi-
cient for sensory alteration was 0.89 for the
interval of 17 weeks, and 0.81 for the interval of
52 weeks. The test–retest correlation coefficient
for neuropathic pain was 0.85 for the interval of
17 weeks, and 0.78 for the interval of 52 weeks.
The test–retest reproducibility figures of the nerve
function tests were also scarcely influenced by the
length of the test–retest interval. Test–retest cor-
relation coefficients of the nerve function tests, for
the interval of 52 weeks, were between 0.46 and
0.97 (data not shown). The only nerve function
test that was influenced by the length of the
test–retest interval was the MNCVtibial. The test–
retest correlation coefficients were 0.70 and 0.46,
for the intervals of 17 and 52 weeks, respectively.
For the assessments of symptom severity and
nerve function tests the SDD was calculated for
the outcomes of test and retest at baseline com-
pared to 17 weeks, and baseline compared to 52
weeks. The SDDs of the measurements of symp-
tom severity and nerve function tests, for the
test–retest interval of 17 weeks, are presented in
Table 3. The SDD (standardized to the corre-
sponding mean of test and retest, group size=
100) of the assessment of sensory alteration was
almost the same as the SDD of the assessment of
neuropathic pain (percentage of difference for the
corresponding mean: 9% vs 12%). The SDDs of
the assessments of nerve conduction velocities
were smaller than the SDDs of the assessments of
VPT, and the SDDs of the assessments of VPT
were smaller than the SDDs of the assessments of
TDT. The difference percentages for the corre-
sponding mean were 3–4% for nerve conduction
velocities, 9% and 14% for VPT, and 21% and
28% for TDT. The figures for the test–retest
interval of 52 weeks were similar (data not
shown). The SDDs of both the assessments of
symptom severity and the nerve function tests,
were not influenced by the length of the test–
retest interval of 17 and 52 weeks, respectively.
5. Discussion
There is no ‘gold standard’ available for the
assessment of polyneuropathy. Therefore, we ex-
amined the construct validity of the measurement
of symptom severity, by calculating the correla-
tions between the outcomes of a number of tests
of small and large nerve fibre function and symp-
tom severity. The nerve function tests we used,
have been recommended as valid and repro-
ducible measurements of the severity of polyneu-
ropathy [15–18]. Moreover, we have confirmed
that the reproducibility of the nerve function tests
was also acceptable when they were performed in
our research centre. Therefore, we were able to
use these tests for the construct validation of the
measurement of symptom severity.
In the literature, it has been suggested that
painful and painless neuropathy are two separate
clinical conditions. Therefore, theoretically, we ex-
pected small nerve fibre function to be associated
with the severity of neuropathic pain, and large
nerve fibre function to be associated with the
severity of symptoms of sensory alteration [10–
14]. However, in the present study, pain was not
found to be predominantly associated with small
nerve fibre function, and sensory alteration was
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not found to be predominantly associated with
large nerve fibre function. Our results are in keep-
ing with previous reports of nerve biopsy studies
on this issue [26,27]. In these studies, a typical
pattern of nerve fibre damage or regeneration of
nerve fibres in diabetic painful polyneuropathy
could not be demonstrated.
Yet, it remains uncertain whether small and
large fibre involvement in diabetic polyneuropa-
thy are two separate clinical conditions, or
whether the small and large fibre type represent
either side of a continuous spectrum of fibre
damage [28,29]. However, an explanation of our
results could be, that we included a high percent-
age of patients with an advanced stage of nerve
damage. At baseline, the measurement of
SNCVsural was not possible in 59% of the patients.
This is suggestive for advanced nerve damage and
therefore, the included patients might have been
beyond the stage of painful small nerve fibre
polyneuropathy. This explanation of our results is
in keeping with the paper of Benbow et al. In that
paper, in a prospective study, it was demonstrated
that neuropathic pain tends to improve with time
and small nerve fibre function continues to deteri-
orate. They concluded that measures of small
nerve fibres do not predict the evolution of pain-
ful symptoms [30].
The results in our study do show however, that
sensory alteration performed better than neu-
ropathic pain with regard to both large and small
nerve fibre function. This is an indication that the
sensory alteration sub–scale is more useful for the
assessment of diabetic polyneuropathy in daily
clinical practice than the neuropathic pain sub-
scale.
We also assessed reproducibility, including the
SDD in a group of 100 patients, and the influence
of the length of the test–retest interval on these
test-characteristics of the measurement of neu-
ropathic symptom severity and of nerve function
tests. Insight into the reproducibility and SDD of
tests is important, because these test-characteris-
tics can directly influence the conclusions drawn
from clinical trials. In a stable patient-population
with polyneuropathy the outcome of nerve func-
tion testing should also be stable. However, if the
clinical status of polyneuropathy improves, e.g.
due to medication, a change should be detected.
During the course of the present study, the nerve
function of the patients remained stable. There-
fore, in order to assess the ability of the tests to
detect changes in clinical trials, we assessed the
SDD in a group of 100 patients. The SDD is a
measurement of reproducibility within certain
groups of patients. A test with a poor reproduci-
bility has a large SDD, in which case the ‘signal’
has to be relatively loud to overcome the ‘noise’.
It is, therefore, probably only able to detect rela-
tively large intervention effects in clinical trials.
The results of the present study indicate an
acceptable degree of reproducibility of the assess-
ment of symptom severity, using the DSC-Type 2,
and of the nerve function tests. The influence of
the length of the test–retest time interval on the
reproducibility of almost all tests appeared to be
small. Only for the MNCV measurements of the
tibial nerve a longer test–retest time interval re-
duced reproducibility according to the correlation
coefficients. This is a surprising finding because
we performed the test procedure in the same
standardized manner for both MNCV measure-
ments. In addition, in literature, especially nerve
conduction studies are recommended because of
their reliability [18]. Therefore, it could be a
chance finding which remains subject to confirma-
tion from other studies.
A good test–retest correlation of a test does not
always implicate a good performance concerning
its smallest detectable statistical significant differ-
ence on group level that is standardized to the
corresponding mean of the tests. This is clearly
demonstrated in Table 3. The test–retest correla-
tion of the MNCV of the ulnar nerve in compari-
son to the TDTwarmth is 0.56 and 0.76,
respectively, with a SDD standardized to the cor-
responding mean of 3% and 21%, respectively.
The assessments of symptom severity, using the
DSC-Type 2, proved to have a small SDD. There-
fore, the standardized measurement of symptom
severity is a useful method of monitoring the
course of polyneuropathy in clinical trials. With
regard to the nerve function tests, the testing of
nerve conduction velocities proved to have the
smallest SDD. The testing of the TDTwarmth and
the TDTcold turned out to have a larger SDD than
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the testing of VPT. This finding was consistent for
both test–retest intervals. In addition, several pre-
vious reports pointed out that the reproducibility
of TDT testing is poor when compared to VPT
testing [18,24]. Therefore, the TDT might be less
useful than the nerve conduction velocity tests
and the VPT for monitoring the course of
polyneuropathy in clinical trials.
Symptoms of polyneuropathy and nerve func-
tion may be influenced by changes in the level of
glycaemic control. [31,32] In the present study a
possible influence of glycaemic control on the
outcomes of the study was minimized because,
according to HbA1c measurements, a stable gly-
caemic control was maintained during the course
of the study.
In conclusion, we found no indication that pain
was predominantly associated with small nerve
fibre function, or that sensory alteration was pre-
dominantly associated with large nerve fibre func-
tion. However, sensory alteration showed a
stronger and more consistent association than
neuropathic pain with the measurements of both
large and small nerve fibre function. Therefore,
the assessment of the severity of sensory alteration
can be useful in the assessment of polyneuropathy
in daily clinical practice.
The standardized assessment of symptom sever-
ity, using the DSC-Type 2, as well as the nerve
function tests, proved to be sufficiently repro-
ducible. Moreover, according to the SDD, the
measurement of symptom severity can be useful
for monitoring the course of polyneuropathy in
clinical trials. Furthermore, of the nerve function
tests studied, the TDT testing appears be less
useful than the nerve conduction velocity testing
and VPT for monitoring the course of polyneu-
ropathy in clinical trials.
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